Sort by: Date / Relevance
MEB 14: Parallel importation: marketing authorisation and maintenance
Parallel import is the importation – and subsequent marketing in the Netherlands – of a medicinal product authorised elsewhere in ...
Strategic Business Plan 2020-2024
This Strategic Business Plan (SBP) describes the strategic direction of the Medicines Evaluation Board (MEB) in the coming period ...
MEB 13: Nomenclature of pharmaceutical products
This document describes the requirements which the marketing authorisation holder has to fulfil when submitting a proposal for a ...
MEB 6: Labelling of pharmaceutical products
The presentation of the primary and secondary packaging of a medicinal product are determining factors in the recognition of a ...
MEB Science Day 2020 - Presentation Fiona Sewell
MEB Science Day 2020 - Presentation Coenraad Hendriksen
MEB Science Day 2020 - Presentation Coen Stalpers
MEB Science Day 2020 - Presentation Roos Masereeuw
MEB Science Day 2020 - Presentation Peter van Meer
MEB 44: Direct Healthcare Professional Communications (DHPCs)
This document is based on the Guideline on Good Pharmacovigilance Practices (GVP) Module XV – Safety communication, and is aimed ...